Platelet Pathophysiology: Unexpected New Research Directions
Alan D. Michelson,Andrew L. Frelinger III,Robin L. Haynes,Hannah C. Kinney,Thomas Gremmel
DOI: https://doi.org/10.1055/s-0044-1787663
2024-06-19
Seminars in Thrombosis and Hemostasis
Abstract:We are very honored that our 2016 review of platelet physiology[1] is one of the top three most downloaded papers in Seminars and Thrombosis and Haemostasis from 2014 to 2023. But why study platelet physiology? Because these remarkable little cells play key roles in many important pathophysiological processes, including thrombosis, hemorrhage, inflammation, antimicrobial host defense, wound healing, angiogenesis, and tumor growth and metastasis.[2] In addition to primary disorders of platelet number and function, platelets have a critical role in many other very common diseases, including coronary artery disease, stroke, peripheral vascular disease, and diabetes mellitus.[2] There remain many incompletely understood aspects of platelet physiology and its relationship to diseases, a few examples of which are the role of platelets in innate and adaptive immunity,[3] [4] the genetic basis of thrombocytopenia,[5] the role of platelet activation in coronavirus disease 2019,[6] the role of platelet activation in liver disease,[7] and novel targets for antiplatelet therapy.[8] [9] [10] But science in general, and the study of platelet physiology in particular, can sometimes lead researchers in an unexpected new direction, as will be discussed in this commentary focused on the relationship between platelet function and sudden infant death syndrome (SIDS). SIDS is defined as the sudden unexpected death of an apparently healthy infant less than 1 year of age that remains unexplained despite a complete autopsy with ancillary testing, examination of the death scene, and review of the clinical history.[11] [12] SIDS is the leading cause of postneonatal mortality in the United States.[13] [14] [15] There are no currently available biomarkers of SIDS in living infants. However, a subset of infants who die of SIDS have abnormalities in the neurotransmitter, serotonin (5-hydroxytryptamine [5-HT]) and the adaptor molecule, 14-3-3 pathways in regions of the brain involved in gasping, response to hypoxia, and arousal ([Fig. 1]).[16] [17] [18] [19] [20] [21] Serotonin is synthesized in the gut, where it is released primarily after stimulation of enterochromaffin cells.[22] [23] [24] Once 5-HT enters the intestinal vasculature, it is sequestered inside platelets by the 5-HT transporter ([Fig. 1]), and then into dense granules by the vesicular monoamine transporter ([Fig. 1]). Approximately 95% of the 5-HT in blood is carried in platelet-dense granules,[25] and serum contains the secretion products of activated platelets, including their dense granules. Platelet activation leads to secretion of dense granule contents, and the secreted 5-HT binds to the platelet surface 5-HT receptor 5-HT 2A ([Fig. 1]), activating signaling pathways that amplify initial platelet activation.[26] [27] [28] Downstream events following 5-HT binding to 5-HT 2A include increases in cytosolic calcium and F-actin ([Fig. 1]). Because (a) approximately 20 to 80% of SIDS deaths are associated with 5-HT receptor (5-HT 1A or 5-HT 2A/C ) binding abnormalities in regions of the brainstem critical in homeostatic regulation,[29] [30] (b) approximately 95% of the 5-HT in blood is carried in platelet-dense granules[25] and serum contains the secretion products of activated platelets (including their dense granules), and (c) blood platelets have similar 5-HT signaling pathways to brain neurons ([Fig. 1]), we hypothesized that SIDS is associated with an alteration in serum 5-HT levels. Indeed, we demonstrated that serum 5-HT, adjusted for postconceptional age, was significantly elevated (95%) in SIDS infants ( n = 61) compared with autopsied controls ( n = 15; SIDS, 177.2 ± 15.1 [mean ± SE] ng/mL vs. controls, 91.1 ± 30.6 ng/mL; p = 0.014), as determined by ELISA.[31] This increase was validated using high-performance liquid chromatography. Thirty-one percent (19/61) of SIDS cases had 5-HT levels greater than 2 SD above the mean of the controls, thus defining a subset of SIDS cases with elevated 5-HT.[31] There was no association between genotypes of the serotonin transporter promoter region polymorphism and serum 5-HT level. This study demonstrated that SIDS is associated with peripheral abnormalities in the 5-HT pathway, and that high serum 5-HT may serve as a potential forensic biomarker in autopsied SIDS infants with serotonergic defects.[31] Because (a) brain neurons have 5-HT and 14-3-3 signaling pathways which are abnormal in SIDS ([Fig. 1]) and (b) blood platelets have similar 5-HT and 14-3-3 signaling pathways to neurons ([Fig. 1]), we then hypothesized that SIDS is, at least in part, a multiorgan dysregulation of 5-HT and that platelets may be -Abstract Truncated-
peripheral vascular disease,hematology